Method for producing a drug delivery system

Inventors

Schneeberger, Achim • Kühne, Klaus • KERSCHBAUMER, Helmut • VASIC, Srdan

Assignees

Exentis Knowldege GmbH • Laxxon Medical AG • Exentis Knowledge GmbH

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12285527-B2

Patent

Publication Date

2025-04-29

Expiration Date


Abstract

The present invention relates to a method for producing a drug delivery system. The method comprises the steps of screen-printing a base paste, and curing the base paste. Furthermore, the method comprises the steps of screen-printing a first paste separate to the base paste, and curing the first paste.

Core Innovation

The invention relates to a method for producing a drug delivery system that is soluble in body fluids. The method comprises screen-printing a base paste and curing the base paste, then screen-printing a first paste separate to the base paste and curing the first paste, where the first paste comprises a therapeutically effective amount of a first active pharmaceutical ingredient, API.

In the resulting drug delivery system, the first paste is inhomogeneously arranged in the base paste along three dimensions, and the concentration of the first API varies throughout the drug delivery system. A transition between an area with a high API concentration and an area with a low API concentration is smooth, and upon application of the drug delivery system, release of the first API occurs at a varying rate.

The pastes are soluble in body fluids such that the drug delivery system is soluble in body fluids. The first API is an anti-inflammatory agent, and the approach enables predetermined, therapy-tailored release behavior driven by the inhomogeneous API arrangement and the varying concentration profile through the device.

Claims Coverage

The independent claim covers a sequential screen-printing and curing method that forms a body-fluid-soluble drug delivery system with an inhomogeneous API concentration profile that drives varying-rate release upon application; the independent claim includes 7 principal inventive features.

Sequential screen-printing and curing of base and API paste

The method comprises screen-printing a base paste; curing the base paste; screen-printing a first paste separate to the base paste; and curing the first paste.

Therapeutically effective first API in separate paste

The first paste comprises a therapeutically effective amount of a first active pharmaceutical ingredient, API.

Body-fluid solubility of base and API paste

The base paste and the first paste are soluble in body fluids such that the resulting drug delivery system is soluble in body fluids.

Inhomogeneous arrangement of first paste throughout base paste along three dimensions

The base paste is provided as a three-dimensional body and the separate first paste is inhomogeneously arranged throughout the base paste along the three dimensions.

Varying first API concentration through the drug delivery system

The concentration of the first API varies throughout the drug delivery system.

Smooth transition between high and low API concentration regions

A transition from an area in the drug delivery system with a high API concentration to an area with a low API concentration is smooth.

Varying-rate release driven by the concentration profile

Upon application of the drug delivery system the release of the first API occurs at a varying rate.

First API is an anti-inflammatory agent

The first API is an anti-inflammatory agent.

Overall claim coverage defines a drug delivery system production route where a base paste and a separate API-containing paste are screen-printed and cured to create an inhomogeneously arranged three-dimensional API distribution. A smooth high-to-low concentration transition and a varying concentration profile are required so that API release occurs at a varying rate upon application, and the first API is limited to an anti-inflammatory agent.

Stated Advantages

Enables varying-rate release by using an inhomogeneous arrangement of the first API concentration through the drug delivery system.

Provides a smooth transition between high and low API concentration regions.

Documented Applications

No documented applications found

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.